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ABSTRACT
Vascular Endotelial Growth Factors C and D (VEGF-C and VEGF-D) are crucial 
regulators of lymphangiogenesis, a main event in the metastatic spread of breast 
cancer tumors. Although inhibition of lymphangiogenic gene expression might be a 
useful therapeutic strategy to restrict the progression of cancer, the factors involved 
in the transcriptional repression of these genes are still unknown. We have previously 
shown that Nuclear Receptor Corepressor 1 (NCoR) and the thyroid hormone receptor 
β1 (TRβ) inhibit tumor invasion. Here we show that these molecules repress VEGF-C 
and VEGF-D gene transcription in breast cancer cells, reducing lymphatic vessel 
density and sentinel lymph node invasion in tumor xenografts. The clinical significance 
of these results is stressed by the finding that NCoR and TRβ transcripts correlate 
negatively with those of the lymphangiogenic genes and the lymphatic vessel marker 
LYVE-1 in human breast tumors. Our results point to the use of NCoR and TRβ as 
potential biomarkers for diagnosis or prognosis in breast cancer and suggest that 
further studies of these molecules as potential targets for anti-lymphangiogenic 
therapy are warranted.
INTRODUCTION
Metastasis is the main cause of cancer-related 
deaths. Although some malignant tumors metastasize 
via the bloodstream most epithelial cancers, including 
breast tumors, first spread via lymphatic vessels to 
their regional lymph nodes and indeed the detection 
of tumor cells within the sentinel node has a main 
importance for patient prognosis [1, 2]. Expression of 
the lymphangiogenic growth factors by the tumor cells 
induces lymphangiogenesis, the growth and enlargement 
of lymphatic vessels, playing a crucial role in tumor 
dissemination [3–6]. Tumor lymphangiogenesis is 
mostly due to the proliferation and sprouting of pre-
existing vessels, rather than to incorporation of 
circulating endothelial progenitor cells and is at least 
in part mediated by VEGF-C and to a lesser extent 
VEGF-D [3, 5, 7–11]. Lymph vessel density correlates 
with nodal status and is a prognostic factor in breast 
cancer [7, 12–15]. Tumor-associated macrophages can 
also produce lymphangiogenic factors contributing to 
vessels formation [16], thus showing the importance of 
the tumor microenvironment in this process. In addition, 
the lymphatic endothelial cells produce chemokines 
such as the stromal-derived factor 1 (or CXCL12), 
which bind CXCR4 receptors in the tumor cells 
[17, 18], facilitating their migration toward the 
lymphatic vessel [19]. 
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NCoR (or Nuclear Corepressor-1) plays an 
important role in gene silencing. This corepressor 
associates with histone deacetylases (HDACs) and is 
recruited to target genes by interaction with nuclear 
receptors and other transcription factors, causing 
chromatin compaction and blocking transcription [20–23]. 
Through regulation of gene expression this corepressor 
could modulate cancer cell biology. Indeed, NCoR 
mutations have been found in breast tumors, and in these 
tumors frame-shift or nonsense inactivating mutations of 
the NCoR gene have been identified as driver mutations 
[24–26]. These observations support the findings that low 
NCoR expression is associated with invasive breast tumors 
[27, 28], a shorter relapse-free survival [29] and 
resistance to anti-estrogen treatment [30], suggesting the 
role of NCoR as a tumor suppressor. In agreement with 
this hypothesis, NCoR silences transcription of genes 
associated with metastatic growth and poor outcome in 
cancer patients, inhibiting tumor growth, invasion and 
metastatic potential in xenograft mouse models [31]. 
Furthermore, it has been demonstrated the existence of a 
positive auto-regulatory loop that maintains NCoR gene 
expression, suggesting that loss of NCoR expression 
can confer an advantage to the tumor cell, contributing 
to tumor progression even in the absence of NCoR gene 
mutations. 
The actions of the thyroid hormones thyroxine 
(T4) and triiodothyronine (T3) are mediated by 
binding to the nuclear thyroid hormone receptors 
(TRs). Although the thyroid gland produces more T4, 
T3 is formed by deiodination of T4 in extrathyroidal 
tissues and is believed to be the active hormone since 
TRs show a higher binding affinity for T3 than for T4 
[32]. TRs and particularly the TRβ isoform can have 
tumor suppressor actions. TRβ mutations, anomalous 
subcellular localization and biallelic inactivation of 
this gene by promoter methylation has been found in 
breast tumors [33–35]. Furthermore, expression of TRβ 
in breast cancer cells reduces tumor growth [36, 37]and 
has a strong inhibitory effect on invasion, extravasation, 
and metastasis formation in immunodeficient mice 
[38]. TRβ induces NCoR expression and this induction 
appears to be an essential mediator of the tumor 
suppressive and anti-metastatic actions of the receptor. 
Moreover, both NCoR and TRβ are downregulated in 
the more aggressive human estrogen receptor negative 
(ER−) breast tumors with respect to the ER+ tumors 
with a better prognosis, existing a positive correlation 
between transcript levels of the receptor and the 
corepressor [31]. 
In this work we tested the possibility that NCoR and 
TRβ could regulate the expression of VEGF genes and 
the growth of lymphatic vessels, thus regulating tumor 
invasion. We demonstrate that NCoR and TRβ repress 
transcription of the VEGF-C and VEGF-D genes in breast 
cancer cell lines and tumor xenografts. Furthermore, 
NCoR depletion increases lymph vessel density in the 
tumors and reverses the inhibitory effect of the receptor 
in lymphangiogenesis. The importance of our results is 
supported by the finding of a strong negative correlation 
between the mRNA levels of the lympangiogenic genes 
and either NCoR or TRβ in human breast tumors. This 
correlation is independent of the ER status, although 
lymphangiogenic genes are expressed at significantly 
higher levels in the ER- tumors. Since high VEGF-C and 
VEGF-D levels lead to a poor prognosis in breast cancer, 
our finding that NCoR and TRβ are potent inhibitors 
of these factors suggests that they may serve as novel 
therapeutic targets to inhibit lymphangiogenesis and breast 
tumor progression.
RESULTS
NCoR represses transcription of the VEGF-C 
and VEGF-D genes in breast cancer cell lines
To analyze a possible correlation between NCoR and 
VEGF-C and VEGF-D gene expression, we first measured 
their transcript levels in several human breast cancer cell 
lines, both ER+ and ER-.  NCoR mRNA was significantly 
higher in the ER+ MCF-7 and ZR75–1 cells than in the 
very aggressive HCC-1954 cells and in the MDA-MB-231 
cells, while VEGF-C and VEGF-D transcripts exhibited an 
opposite pattern, being lower in the ER+ positive cell lines 
(Figure 1A). Although other factors different from NCoR 
could be responsible for the negative association with 
lympangiogenic gene expression in these independently-
derived cell lines, the inverse relationship observed 
suggested that NCoR could repress VEGF-C and VEGF-D 
gene transcription. Proximal promoter sequences appear 
to play an important role in the control of VEGF-C and 
VEGF-D transcription [39, 40]. To analyze if NCoR could 
bind to the regulatory region of these lymphangiogenic 
genes, we performed chromatin immunoprecipitation 
(ChIP) assays with an NCoR antibody and two different 
fragments of the 5´-flanking regions of these genes. 
Significant NCoR association to the -235/+13 region of the 
VEGF-C gene was observed in MCF-7 and ZR75-1 cells, 
while NCoR binding was much lower in MDA-MB-231 
and HCC-1954 cells (Figure 1B). However, NCoR did not 
bind to the immediate upstream region of the VEGF-C 
promoter in any cell line. A very strong binding of the 
corepressor was found in the ER+ cells when the proximal 
-423/-119 region of the VEGF-D gene was analyzed and 
again NCoR binding to these sequences was very low 
in the ER- cells. However, NCoR was not recruited to 
the -608/-430 region of the VEGF-D gene, previously 
proposed to be necessary for VEFG-D transcription 
[39, 40] (Figure 1B).
To study the functionality of NCoR binding to 
the regulatory region of the lymphangiogenic genes, 
MDA-MB-231 and MCF-7 cells were transfected with 
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a control siRNA or with an NCoR specific siRNA. 
Transfection of siNCoR very effectively reduced NCoR 
transcripts in the cells, and VEGF-C and VEGF-D gene 
expression was significantly increased upon NCoR 
depletion (Figure 1C). In accordance with the different 
levels of NCoR expression and promoter occupancy 
shown in panels A and B, this increase was stronger 
in MCF-7 cells and more moderate in MDA-MB-231 
cells. These results show that the VEGF-C and VEGF-D 
genes are bona fide targets of NCoR in breast cancer 
cells. 
TRβ silences VEGF-C and VEGF-D gene 
transcription
Since TRβ can increase NCoR mRNA and protein 
levels [31] and this corepressor silences VEGF-C and 
VEGF-D gene expression, we next examined the possibility 
Figure 1: NCoR represses VEGF-C and VEGF-D gene transcription NCoR represses VEGF-C and VEGF-D gene 
transcription. (A) NCoR, VEGF-C and VEGF-D mRNA levels (means ± S.D) were measured by quantitative real-time PCR in 
the indicated human breast cancer cells lines and are expressed relative to the values obtained in MDA-MB-231 cells. (B) chromatin 
immunoprecipitation (ChIP) assays with NCoR antibody and control IgG were performed with the indicated fragments of the VEGF-C and 
VEGF-D gene promoters. Results obtained in two different experiments are shown. (C) levels of the indicated transcripts were determined 
in cells transfected with control or NCoR siRNAs 72 h before. Data (means ± SD) are expressed relative to the values obtained in cells 
transfected with siControl. Significance of t-test between cells transfected with siControl and siNCoR are indicated. ***P < 0.001.
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that TRβ could reduce the expression of lymphangiogenic 
genes and the potential role of NCoR in this repression. 
With this purpose we first compared VEGF-C and VEGF-D 
transcripts in parental MDA-MB-231 cells and in cells 
expressing TRβ in a stable manner (from now on MDA 
and MDA-TRβ cells, respectively). As expected from the 
induction of NCoR expression by the receptor observed in 
several cell types [31], MDA-TRβ cells expressed higher 
NCoR protein and mRNA levels than the parental cells 
(Figure 2A and 2B), and also showed significantly lower 
levels of VEGF-C and VEGF-D transcripts. Silencing was 
observed in the absence of ligand, but incubation with 
T3 further reduced mRNA levels of lymphangiogenic 
genes (Figure 2B), showing the role of NCoR and TRβ 
as inhibitors of VEGFs gene expression in these cells. To 
analyze the role of NCoR in the repressive effect of TRβ, 
we next examined VEGF-C and VEGF-D mRNA levels in 
MDA and MDA-TRβ cells transfected with siControl or 
siNCoR (Figure 2C). NCoR depletion increased VEGF-C 
and VEGF-D transcripts both in parental and MDA-
TRβ cells, strongly relieving the repressive effect of the 
unliganded TRβ  and abolishing the inhibitory effect of T3 
(Figure 2D). Therefore, NCoR appears to play a major role 
in lymphangiogenic gene silencing by TRβ. Since NCoR2 
(or SMRT) could have redundant effects with NCoR in 
transcriptional repression, we conducted similar experiments 
in cells transfected with a specific SMRT siRNA. In contrast 
with NCoR, selective SMRT depletion (Figure 2E) did not 
increase VEGF-C and VEGF-D transcripts in MDA cells 
and was unable to relieve the inhibitory effects of TRβ in 
MDA-TRβ cells (Figure 2F), showing that SMRT does not 
participate in regulation of the lymphangiogenic genes in 
Figure 2: NCoR depletion increases VEGF-C and VEGF-D gene expression. (A) Western blot analysis of TRβ and 
NCoR in parental MDA-MB-231 cells and in cells stably expressing the receptor (MDA and MDA-TRβ, respectively). ERK 
was used as a loading control. (B) mRNA levels of the indicated genes were determined in cells treated in the presence and 
absence of 5 nM T3 for 36 h. (C) NCoR and ERK levels after 72 h of transfection with siControl or siNCoR. (D) Transcript 
levels of NCoR, VEGF-C and VEGF-D in cells transfected with siControl or siNCoR and treated with and without T3. 
(E) SMRT and ERK levels after 72 h of transfection with siControl or siSMRT. (F) Transcript levels of SMRT, VEGF-C and VEGF-D in 
cells transfected with siControl or siSMRT and treated with and without T3. All data are means ± S.D and are expressed relative to the 
values obtained in untreated parental cells transfected with the control siRNA. Significance of ANOVA post-test among the indicated 
groups is shown as * P < 0.05,  **P < 0.01 and ***P < 0.001.
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these cells. To further investigate the mechanism by which 
NCoR and TRβ regulate transcription of prometastatic genes, 
we conducted transient transfection studies with luciferase 
constructs containing the 5′-flanking region of the VEFG-C 
gene [39] in MDA and MDA-TRβ cells. As shown in 
Figure 3A, activity of the -1059/+206 promoter region was 
lower in the TRβ expressing cells and was further reduced 
in the presence of T3. Similar results were obtained with a 
shorter construct (−201/+206). However, no changes were 
observed when cells were transfected with the luciferase 
plasmid alone, indicating that the proximal promoter 
region that binds NCoR in ChIP assays also contains the 
response elements responsible for repression of VEGF-C 
gene transcription by TRβ. NCoR knock-down in cells 
transfected with the -201/+206 plasmid increased promoter 
activity in the parental cells, and almost totally reversed the 
inhibition by TRβ and T3 (Figure 3B), recapitulating the 
results obtained with the endogenous transcripts in Figure 
2 and demonstrating again the important role of NCoR in 
VEGF-C gene silencing. In silico analysis of the proximal 
VEGF-C promoter sequences −231/+13 used in the ChIP 
assays revealed the existence of two putative hemisites that 
could bind the thyroid hormone receptor. ChIP assays with 
this region demonstrated that TRβ expression increased 
remarkably the association of NCoR with the VEGF-C 
gene and that this association was enhanced in T3-treated 
cells. TRβ also bound constitutively to the same region 
in MDA-TRβ cells and T3 further increased receptor 
recruitment to the promoter (Figure 3C). These results 
correlated with the lower transcriptional activity of the 
gene under these conditions. The more upstream –550/–232 
sequences recruited neither NCoR nor TRβ, discarding their 
participation in repression by TRβ and confirming that the 
more proximal promoter sequences identified in the transient 
transfection assays appear to be sufficient to mediate gene 
repression by TRβ. Examination of he VEGF-D promoter 
region −423/−119, which binds NCoR, also predicted the 
existence of two hemisites that could act as binding motifs 
for TR (Figure 3D). Although NCoR bound strongly to this 
promoter fragment in MDA-TRβ cells and T3 increased 
this binding, the receptor was absent from this region. This 
result indicates that the hemisites do not act as TR binding 
sequences and that therefore NCoR is not recruited to this 
region by interaction with TRβ. In addition, the −608/−430 
region of the VEGF-D gene has been described to contain 
and atypical hormone response element which could bind 
orphan nuclear receptors [40]. However, TRβ or NCoR 
association with this region was not observed in either MDA 
or MDA-TRβ cells, indicating that this region does not play 
a role in VEGF-D silencing by the corepressor. 
NCoR and TRβ repress VEGF-C and VEGF-D 
expression in ER+ MCF-7 cells
To analyze if the silencing effect of TRβ in 
lymphangiogenic gene expression was restricted to the 
MDA cells or could be extended to other breast cancer 
cells, we next used MCF-7 cells stably expressing high 
levels of TRβ (MCF7-TRβ cells) [37] (Supplementary 
Figure S1A). As shown in Supplementary Figure S1B, 
TRβ expression also increased NCoR expression in MCF7 
cells, while significantly reducing VEGF-C and VEGF-D 
mRNA levels. NCoR deletion also enhanced considerably 
VEGF-C and VEGF-D transcripts in MCF-7 cells and 
reversed the repressive effect of TRβ to a significant 
extent (Supplementary Figure S1C), while SMRT deletion 
did not affect expression of the lymphangiogenic genes 
(Supplementary Figure S1D). These results reproduce 
those obtained in MDA cells, indicating that NCoR, 
but not SMRT, silences VEGF-C and VEGF-D gene 
expression in breast cancer cells independently of the ER 
status, and that NCoR is an important element in TRβ-
dependent repression of these genes.
NCoR and TRβ inhibit tumor lymphangiogenesis
To examine the effect of TRβ and NCoR in tumor 
lymphangiogenesis in vivo, we analyzed VEGF-C and 
VEGF-D gene expression as well as lymph vessel density 
in xenograft studies with MDA and MDA-TRβ cells 
transfected with siControl or siNCoR 72h before orthotopic 
inoculation into the fat mammary pad of nude mice. TRβ-
expressing tumors were smaller and non invasive, but 
they became highly infiltrative in the absence of NCoR 
(Supplementary Figure S2). As expected from the existence 
of an autoregulatory loop that maintains NCoR gene 
expression [31], NCoR transcripts were still depleted in 
tumor xenografts formed by cells transfected with siNCoR 
more than one month before, while TRβ transcripts were 
not altered (Figure 4A). When VEGF-C and VEGF-D 
transcripts were measured, it was found that both genes 
were expressed al lower levels in tumors originated by 
MDA-TRβ cells than by the parental cells transfected 
with a control siRNA. However, NCoR depletion 
markedly enhanced lympangiogenic gene expression in 
both groups and under these conditions the repressive 
effect of TRβ on VEGF-C and VEGF-D expression was 
relieved, corroborating the results obtained in the cultured 
cells (Figure 4A). Transcript levels of mouse LYVE-1 
(or lymphatic vessel endothelial hyaluronan receptor), a 
specific marker of lymphatic vessels [41], was also reduced 
in the tumors formed by MDA-TRβ cells with respect to 
the MDA cells and NCoR depletion increased LYVE-1 
mRNA levels in parallel with the increased expression of 
the lymphangiogenic genes by the tumor cells (Figure 4B). 
Immunochemical detection of LYVE-1 showed that lymph 
vessels had a predominant peritumoral localization in the 
breast tumors formed by MDA cells and that they were 
very scarce in the tumors formed by the MDA-TRβ cells. 
However, vessel density increased significantly in NCoR-
depleted tumors and the inhibitory effect of TRβ in tumor 
lymphangiogenesis was noticeably alleviated  (Figure 4C). 
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Since not only the tumor cells but also the tumor 
microenvironment releases lymphangiogenic factors, we 
next examined mouse VEGF-C and VEGF-D expression 
in the xenografts (Figure 4D). Mouse NCoR levels were 
not altered by the human siRNA, showing the specificity 
of NCoR depletion exclusively in the tumor cells. 
However, host VEGF-C and VEGF-D expression was 
reduced in MDA-TRβ xenografts and increased when 
Figure 3: NCoR is involved in transcriptional inhibition of the VEGF-C and VEGF-D genes by TRβ. (A) Transient 
transfection assays in MDA and MDA-TRβ cells with reporter plasmids of the human VEGF-C promoter extending to nucleotides −1059 
and −201 or the empty plasmid without promoter sequences (e.p). Luciferase activity (means ± S.D) was determined in cells treated for 
36 h in the presence and absence of 5 nM T3 and is expressed relative to value obtained in the untreated cells transfected with the empty 
plasmid. Differences between untreated and T3-treated cells were calculated with the t-test and are indicated as ***P < 0.001. (B) similar 
experiments in cells cotransfected with the −201 plasmid and control or NCoR siRNAs. Luciferase activity (means ± S.D) was measured in 
cells treated with and without T3 and is expressed relative to that obtained in untreated MDA cells transfected with siControl. Statistically 
significant differences of the ANOVA post-test among groups of MDA and MDA-TRβ cells are indicated as *P < 0.05,  **P < 0.01 and 
***P < 0.001. (C) ChIP assays with the indicated fragments of the VEGF-C and VEGF-D promoters and NCoR and TRβ antibodies in 
cells treated in the presence and absence of T3 for 1 h. Schemes of the promoter fragments used showing the existence of putative binding 
sites for TR (TRE hemisites) and for other transcription factors are depicted. Results are expressed as % of the input after subtracting the 
values obtained after immunoprecipitation with control IgG that were always lower than 1% of the input. Data shown are the mean of two 
independent experiments.
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NCoR was depleted in the tumor cells. This indicates a 
reciprocal interplay between the tumor microenvironment 
and the tumor cells to collaboratively regulate tumor 
lymphangiogenesis. 
Since TRβ expression reduces tumor size while 
tumors are bigger upon NCoR depletion (Supplementary 
Figure S2A), there was the possibility that the observed 
changes in lymphangiogenesis could be secondary to 
the different tumor size. Therefore, we next compared 
tumors formed by MDA and MDA-TRβ cells transfected 
with siControl or siNCoR when they reached the same 
volume (1 cm3). The results obtained confirmed again 
that NCoR depletion persisted for a very long time, 
since NCoR mRNA was significantly reduced both in 
MDA and MDA-TRβ cells originally transfected with 
siNCoR, whereas VEGF-C and VEGF-D transcripts were 
strongly induced, thus confirming the results obtained 
in the different size xenografts excised after one month 
(Supplementary Figure S3A). In addition, TRβ mRNA 
was not altered in the absence of NCoR, suggesting 
again that NCoR is the main mediator of the inhibitory 
effects of TRβ in lymphangiogenic gene repression. 
Moreover, LYVE-1 gene expression followed a similar 
pattern (Supplementary Figure S3B), and mouse VEGF-C 
and VEGF-D mRNAs were induced by NCoR depletion 
(Supplementary Figure S3C), suggesting again that the 
absence of this corepressor induces changes in the tumor 
cells that affect the tumor microenvironment. 
NCoR depletion increases the presence of tumor 
DNA in the sentinel node 
As expression levels of the lymphangiogenic factors 
correlate with lymph node metastasis, the sentinel lymph 
Figure 4: NCoR and TRβ inhibit tumor lymphangiogenesis. (A) NCoR, TRβ, VEGF-C and VEGF-D mRNA levels in xenografts 
of MDA and MDA-TRβ cells. Cells were transfected with siControl or siNCoR 72 h before orthotopical inoculation into nude mice and 
animals were sacrificed 4 weeks later. (B) relative mouse LYVE-1 mRNA levels in the different groups of tumors. (C) representative 
immunohistochemical staining of LYVE-1 in the tumors, showing the presence of peritumoral lymphatic vessels. Bars: 100 µM.The 
right panel shows the quantification of the number of lymphatic vessels/microscopic field (means ± S.E) in the tumors. (D) mouse NCoR, 
VEGF-C and VEGF-D transcripts (means ± S.E) in the xenografts. mRNA levels (means ± S.E) are expressed relative to the values 
obtained in MDA tumors transfected with siControl. Statistically significant differences between tumors generated from breast cancer 
cells transfected with siControl and siNCoR, analyzed by ANOVA and Bonferroni post-test, are indicated as * P < 0.05,  **P < 0.01 and 
***P < 0.001. 
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nodes of the mice were dissected and the presence of breast 
tumor DNA was studied by means of quantification of 
human Alu sequences. As shown in Figure 5A, in parallel 
with the changes in VEGF-C and VEGF-D expression, the 
presence of tumor DNA in the sentinel node was decreased 
in animals inoculated with TRβ-expressing cells, while 
NCoR depletion resulted in a significant increase in the 
amount of tumor DNA reaching the node and in a partial 
reversion of the inhibitory effect of TRβ.
The lymphatic endothelial cells produce chemokines 
that can attract the tumor cells expressing their receptors, 
supporting their migration toward the lymphatic vessels. 
Interestingly, it has been previously shown that CXCR4 is 
an NCoR and TRβ target gene [31, 38]. Therefore, we next 
analyzed expression of this receptor and its ligand in the 
tumors. Confirming previous results, CXCR4 expression 
was reduced in the TRβ-expressing tumors and NCoR 
depletion resulted in a significant increase in its expression 
(Figure 5B). Remarkably, mouse CXCL12 gene expression 
followed a similar pattern (Figure 5B), suggesting again 
the importance of the cross-talk between the breast 
cancer cells and the cells in the microenvironment in the 
regulation of tumor spreading.
Correlation of NCoR and TRβ with 
lymphangiogenic gene expression in human 
breast tumors
To examine whether or not the repressive role of 
NCoR in lymphangiogenesis could be also demonstrated in 
human tumors, we next performed immunohistochemical 
staining of NCoR and lymphatic vessels in samples from 
6 ER+ and 5 ER- breast tumors. Figure 6A shows that 
NCoR staining was stronger in ER+ tumors than in ER- 
tumors in which the majority of the cells did not show 
nuclear staining with the NCoR antibody. These results 
confirm previous data with other tumor series in which 
transcript levels of NCoR were also reduced in ER- tumors 
[31]. In contrast, staining with the lymphatic vessel 
marker Podoplanin showed an opposite pattern with an 
increased number of peritumoral lymphatic vessels in 
the ER- tumors, suggesting that NCoR might also inhibit 
lymphangiogenesis in human breast tumors. 
It has been shown that not only NCoR but also 
TRβ transcripts were markedly reduced in RNA samples 
from ER- tumors when compared with ER+ tumors [31]. 
To further explore the potential role of these molecules 
in tumor lymphangiogenesis, we next quantitated LYVE-
1, VEGF-C and VEGF-D transcripts in the same tumor 
series finding that, as expected, expression of these 
genes was higher in the more aggressive ER- breast 
tumors (Figure 6B). To examine the possible existence 
of a negative correlation between NCoR or TRβ and 
lymphangiogenic gene expression, NCoR (Figure 6C) and 
TRβ (Figure 6D) mRNA levels were plotted against LYVE-
1, VEGF-C and VEGF-D mRNAs. Statistical analysis 
showed that, indeed, there was a statistically significant 
negative correlation in all cases. The inverse relationship 
between transcript levels of NCoR and these genes was 
also found when ER+ and ER- tumors were considered 
separately (Supplementary Figure S4), and this also 
occurred when LYVE-1, VEGF-C and VEGF-D mRNAs 
were plotted against TRβ mRNA levels (Supplementary 
Figure S5). These results further indicate that NCoR is 
also a potent inhibitor of lympangiogenesis in human 
breast tumors and a downstream effector of TRβ in this 
process.
DISCUSSION
Studies in lymphangiogenesis have shown the key 
role of two members of the VEGF family, VEGF-C and 
VEGF-D, which interact with the VEGFR-3 receptor not 
only in the development of the lymphatic system but also 
in promoting tumor lymphangiogenesis and lymphatic 
metastasis [2, 11]. Therefore, identification of the 
mechanisms that regulate expression of these genes may be 
important to understand the molecular basis of lymphatic 
vessel growth and for the potential development of novel 
therapeutic strategies for combating metastasis. Breast 
tumors are particularly interesting at this respect, since 
spreading through the lymphatic system is predominant 
in these tumors. In the present study, we show that the 
corepressor NCoR and the nuclear receptor TRβ can 
inhibit transcription of the VEGF-C and VEGF-D genes, 
acting as potent repressors of tumor lymphangiogenesis in 
breast cancer xenograft models and correlating negatively 
with the expression of lymphangiogenic genes in human 
breast tumors.
The following findings clearly show that VEGF-C 
and VEGF-D are bona fide target genes for NCoR 
repression: i, breast cancer cells expressing higher NCoR 
mRNA levels express lower levels of the lymphangiogenic 
genes; ii, NCoR associates with the regulatory region of 
these genes in ChIP assays and this association is stronger 
in cells presenting higher levels of the corepressor; iii, 
NCoR depletion with siRNA increases promoter activity 
of the VEGF-C gene in transient transfection studies and 
iv, transfection with NCoR siRNA increases endogenous 
transcript levels of VEGF-C and VEGF-D. In addition to 
NCoR, TRβ also represses expression of lymphangiogenic 
genes, as indicated by the finding that VEGF-C and 
VEGF-D transcripts are significantly lower in breast 
cancer cell lines stably expressing TRβ than in their 
corresponding parental cells that express very low receptor 
levels. The silencing effect of TRβ appears to be mediated, 
at least in part, by the elevated NCoR levels present in 
TRβ expressing cells. This is proved by the result that 
lymphangiogenic transcripts are significantly restored 
upon NCoR depletion. However, at least in the case of 
VEGF-C, TRβ is recruited to the same promoter region 
responsible for NCoR binding and could therefore directly 
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down-regulate transcription. In the case of VEGF-D 
NCoR, but not TRβ, associates with proximal promoter 
sequences. Interestingly, in breast cancer cells neither TRβ 
nor NCoR bind to a region previously reported to mediate 
regulation by some orphan receptors and to be important 
for basal transcription [40]. 
The role of NCoR and TRβ as potent regulators 
of the VEGF-C and VEGF-D genes was confirmed in 
vivo using xenografts. Thus, TRβ expression resulted in 
reduced transcript levels of these genes in the tumors, 
while NCoR depletion had an opposite effect enhancing 
them significantly. Again, the suppressive effect of TRβ 
was significantly reversed in the absence of NCoR, 
reinforcing the idea that NCoR plays a critical role 
in lymphangiogenic gene silencing by the receptor. 
Moreover, although tumor size is an important parameter 
to predict lymph node involvement in breast cancer [42], 
this occurred independently of tumor size, showing that 
direct regulation of lymphangiogenic gene expression is 
not secondary to the differences in tumor growth caused 
by TRβ or NCoR. These results suggested to us that these 
molecules might also suppress tumor lymphangiogenesis. 
Accordingly, histologic analysis showed that NCoR 
depletion was sufficient for promoting tumor 
lymphangiogenesis, resulting in increased LYVE-1 gene 
expression and in increased density of LYVE-1–positive 
lymphatic vessels. Contrarily, TRβ-expressing tumors 
showed significantly reduced LYVE-1 gene expression and 
a very low number of lymphatic vessels, which reappeared 
when NCoR was knocked-down. These lymphatic vessels 
were mainly in the peritumoral area. While intratumoral 
vessels are normally considered as nonfunctional, the 
lymphatic vessels at the periphery of the tumor likely 
serve as conduits for the metastatic cells to reach the 
draining lymph nodes. This has led to the concept that a 
dense lymphatic vasculature in this area would increase 
the number of entry sites of the tumor cells to the vessels 
and consequently metastatic spreading [43]. Accordingly, 
we found an increased amount of tumor DNA reaching the 
sentinel node upon NCoR depletion in the tumors and a 
much lower amount, also partially reversed in the absence 
of the corepressor, when the tumor cells expressed TRβ. 
These changes are compatible with parallel alterations 
in the number of metastatic cells colonizing the draining 
nodes, but the possibility that metastatic lesions were still 
not present and that DNA travelled to the lymph nodes in 
exosomes or by other means cannot be dismissed. Once 
the metastatic cells reach the lymph node they may enter 
a latent stage or further disseminate to other lymph nodes, 
the blood vessels and more distant organs.
The tumor microenvironment, composed by 
endothelial cells, immune cells, fibroblasts, signaling 
molecules and the extracellular matrix provides signals 
to the tumor cells in the form of both cell-cell contacts 
and secreted factors. It is increasingly evident that 
crosstalk between cancer cells and cells of the neoplastic 
microenvironment is a crucial component of invasion 
and metastatic growth [44]. Particularly interesting are 
Figure 5: NCoR depletion increases chemokine expression and sentinel node invasion. (A) sentinel lymph nodes were excised 
from the mice shown in Figure 4 that were inoculated 4 weeks before with MDA and MDA-TRβ cells previously transfected with siControl 
or siNCoR. The presence of the breast cancer DNA in the mice lymph node was assessed by determination of human Alu sequences. 
(B) transcript levels of the human CXCR4 chemokine receptor and of the mouse CXCL12 chemokine, its ligand, in the tumors. Data 
(means ± S.E) are expressed relative to the values obtained in mice injected with the parental cells transfected with siControl. Statistically 
significant differences were analyzed by ANOVA followed by Bonferroni test and are shown as * P < 0.05,  **P < 0.01 and ***P < 0.001.
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the interactions between lymphatic endothelial cells 
and tumor cells to promote cancer cells dissemination. 
Not only the tumor cells secrete VEGFs, but also the 
tumor environment and specifically tumor-associated 
macrophages can function as a second source of 
lymphangiogenic factors [45]. Of interest, we found that 
expression of mouse VEGF-C and VEGF-D transcripts 
is increased in the tumors generated by NCoR-deficient 
breast cancer cells. As mouse NCoR gene expression is not 
altered, this suggests that breast tumor cells with different 
NCoR levels send distinct, still unidentified, signals to the 
macrophages that are able to alter lymphangiogenic gene 
expression. On the other hand, tumor cells may activate 
lymphatic cells to secrete factors that help their transport 
into the lymphatic vessels. Among them, lymphatic 
endothelial cells secrete chemokines such as CXCL12 
that can promote tumor cells expressing the cognate 
receptor CXCR4 to migrate toward the lymphatic vessels, 
promoting a lymphatic microenvironment that supports 
tumor growth [19]. We have confirmed that CXCR4, 
a marker and mediator of breast-cancer metastasis 
[18, 46, 47], is a target for repression by NCoR and TRβ 
[31, 38]. Importantly, our results indicate that NCoR and 
TRβ not only silence the expression of CXCR4 receptors 
in the breast tumor cells, but also reduce the production 
of its ligand, CXCL12, by the tumor environment. The 
CXCL12-CXCR4 chemokine pathway has been shown to 
enhance tumor lymphangiogenesis and to have additive 
effects with the VEGF-C pathway. Furthermore, targeting 
both the chemokine and VEGF-C results in a stronger 
Figure 6: NCoR and TRβ levels correlate negatively with lymphangiogenic gene expresion in human breast tumors. 
(A) NCoR (left panels) and Podoplanin (right panels) immunohistochemistry of representative ER+ and ER- tumors. a: ER+ lobular tumor, b 
ER+ ductal tumor; c and d : ER- ductal tumors. Bars: 100 µM. (B) Whisker plot of LYVE-1, VEGF-C and VEGF-D mRNA levels in ER+ and 
ER- tumors. Data are mean ± S.E of 12 and 14 tumors, respectively. Outliers are shown by a black square. Significance of t-test between ER 
positive and negative tumors are indicated as * P < 0.05,  **P < 0.01. (C) NCoR mRNA levels measured in Ref. were plotted against the 
corresponding LYVE-1, VEGF-C and VEGF-D mRNAs obtained in each sample. The p value and linear regression coefficient obtained are 
shown. (D) results with individual TRβ mRNAs obtained in Ref. 31, plotted against mRNAs of the lymphangiogenic genes.
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inhibition of tumor lymphangiogenesis and lymph node 
metastasis in the breast cancer xenograft model used in 
our study [48]. Therefore, the increased expression of 
these genes in the absence of NCoR would create a highly 
favorable scenario for lymphatic dissemination of breast 
cancer cells.
Besides silencing of VEGFs and chemokine 
receptors, we cannot exclude the possibility that 
NCoR and the receptor might also have additional 
anti-lymphangiogenic effects via modulation of other 
genes. Thus, in addition to VEGFs, a growing number 
of additional factors including IGFs [49], HGF [50] 
and COX2 [51, 52] have been described to promote 
lymphangiogenesis. Interestingly, the HGF receptor c-Met 
or COX2 genes are TRβ and NCoR targets and the receptor 
induces the expression of IGF-BP3, an inhibitor of IGFs 
signaling [31, 38]. Therefore, it is likely that regulation of 
these factors might contribute to the anti-lymphangiogenic 
effects of TRβ and NCoR.
Lymphatic vessel density correlates with metastasis 
and poor outcome in most clinical studies in breast cancer 
and other tumors [3, 7, 8, 12, 14]. Accordingly, we found a 
higher number of lymphatic vessels in the more aggressive 
tumors. Furthermore, not only LYVE-1 mRNA but also 
VEGF-C and VEGF-D mRNAs were lower in ER+ tumors. 
It had been previously shown that NCoR gene expression 
was reduced in the ER- tumors [31] and, remarkably, 
there was a significant negative correlation, independent 
of the ER status, between NCoR and lymphangiogenic 
gene expression further validating that the corepressor 
is an important suppressor of lymphangiogenic genes 
transcription. A significant negative correlation between 
VEGF-C and VEGF-D and TRβ transcript levels was 
also found. This finding reinforces the hypothesis that 
TRβ is an upstream regulator of NCoR and suggests 
that the inhibitory effects of TRβ in human breast tumor 
lymphangiogenesis are most likely mediated by NCoR 
induction. These results suggest that NCoR and TRβ 
might be useful as novel biomarkers in breast cancer 
and as potential predictors of lymphatic dissemination. 
The development of therapeutic agents targeting 
lymphangiogenesis is being considered for the control of 
tumor growth and lymphatic metastasis. Thus, both the 
receptor and the corepressor might be novel therapeutic 
targets in both ER-positive and ER-negative tumors.
MATERIALS AND METHODS
Extended materials and methods are provided in 
Supplementary Materials and Methods. Animal and human 
studies were approved by the Ethics Committee of the 
Consejo Superior de Investigaciones Científicas. NCoR 
and SMRT were knocked-down in cells with specific 
siRNA SMART pools from Dharmacon. Experimental 
procedures for transfections, luciferase reporter assays, 
western blot, mRNA determination by real time PCR 
and chromatin immunoprecipitation assays have been 
published previously and are described together with the 
antibodies and primers used in Supplementary Materials 
and Methods. Tumor formation in nude mice was followed 
for 4 weeks after orthotopic Supplementary Materials and 
Methods inoculation into the mammary pad. Histology 
and immunohistochemistry was performed by standard 
procedures. Significance of ANOVA post-test or the 
Student t-test among the experimental groups indicated 
in the figures is shown as *P < 0.05,  **P < 0.01 and 
***P <0.001.
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